SCHEMBL1362813

SCHEMBL1362813

COc1ccccc1OCCCc1oc(N(C)CCO)nc1-c1ccc(Cl)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHPS P49366 2/20 0.41
ALDH1A1 P00352 4/20 0.38
HSD17B10 Q99714 2/20 0.38
SLC9A5 Q14940 1/20 0.38
THRB P10828 1/20 0.36
MAPK1 P28482 4/20 0.36
TSHR P16473 3/20 0.36
TP53 P04637 1/20 0.36
ALOX15 P16050 1/20 0.36
MAPT P10636 2/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
USP2 O75604 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
GAA P10253 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1361414 0.88 TSHR (0.38) DHPSALDH1A1HSD17B10THRBMAPK1
SCHEMBL1363172 0.86 MAOB (0.40) DHPSALDH1A1HSD17B10THRBMAPK1
SCHEMBL1361698 0.81 MAPT (0.41) DHPSALDH1A1HSD17B10THRBMAPK1
SCHEMBL1360126 0.79 DHPS (0.41) DHPSALDH1A1HSD17B10THRBMAPK1
SCHEMBL1361404 0.75 L3MBTL1 (0.36) DHPSALDH1A1HSD17B10THRBMAPK1
SCHEMBL1361665 0.74 GCGR (0.38) DHPSALDH1A1HSD17B10THRBMAPK1
SCHEMBL962882 0.74 MAPT (0.36) DHPSALDH1A1HSD17B10THRBMAPK1
SCHEMBL1361453 0.74 CYP3A4 (0.38) DHPSALDH1A1HSD17B10THRBMAPK1
SCHEMBL1362462 0.73 L3MBTL1 (0.38) DHPSALDH1A1HSD17B10THRBMAPK1
SCHEMBL1361683 0.73 SLC2A1 (0.44) ALDH1A1HSD17B10TSHRMAPTUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8067453-B2 Oxazole compound to treat or prevent diabetic neuropathy; 4-(4-chlorophenyl)-5-(3-(2-methoxyphenoxy)propyl-2-methyl-1-imidazolyl)oxazole TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-11-29 US disclosed
US-20080269219-A1 Neurotrophin production/secretion promoting agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-10-30 US disclosed
US-7396848-B1 oxazole derivatives to treat diabetic neuropathy and/or other kinds of peripheral neuropathy; 4-(4-chlorophenyl)-5-[3-(2-methoxyphenoxy)propyl]-2-(2-methyl-1-imidazolyl)oxazole TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-08 US disclosed
EP-1206472-B1 OXAZOLE AND THIAZOLE DERIVATIVES AS NEUROTROPHIN PRODUCTION/SECRETION PROMOTING AGENT TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2003-10-01 EP disclosed
US-6605629-B1 Oxazole derivatives; low toxicity TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2003-08-12 US disclosed
EP-1206472-A1 OXAZOLE AND THIAZOLE DERIVATIVES AS NEUROTROPHIN PRODUCTION/SECRETION PROMOTING AGENT Takeda Chemical Industries, Ltd. (JP) 2002-05-22 EP disclosed
WO-2001014372-A2 OXAZOLE AND THIAZOLE DERIVATIVES AS NEUROTROPHIN PRODUCTION/SECRETION PROMOTING AGENT TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2001-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269219-A1 Neurotrophin production/secretion promoting agent BDNF, NGF, NTRK2 DHPS 2390/4885ALDH1A1 937/4885HSD17B10 608/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.